Pro Medicus Ltd (ASX: PME) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Pro Medicus Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $12.14 billion
P/E Ratio 57.97
Dividend Yield 0.48%
Shares Outstanding 104.47 million
Earnings per share 2.243
Dividend per share 0.64
Year To Date Return -42.98%
Earnings Yield 1.73%
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Pro Medicus Ltd (ASX: PME)
    Latest News

    Five young people sit in a row having fun and interacting with their mobile phones.
    Share Gainers

    Why AGL, Evolution Mining, Pro Medicus, and Seven shares are roaring higher

    These shares are having a good time on hump day. But why?

    Read more »

    a man raises his fists to the air in joyous celebration while learning some exciting good news via his computer screen in an office setting.
    Earnings Results

    Pro Medicus shares jump on explosive FY24 growth

    This tech stock has impressed the market again with another strong showing in FY 2024.

    Read more »

    Medical workers examine an xray or scan in a hospital laboratory.
    Healthcare Shares

    One ASX 200 stock with an 'enormous growth path' to buy today

    These two leading experts are bullish on the growth outlook for this ASX 200 stock. But why?

    Read more »

    A group of business people pump the air and cheer.
    Broker Notes

    Top brokers name 3 ASX shares to buy next week

    Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

    Read more »

    A group of people in suits watch as a man puts his hand up to take the opportunity.
    Growth Shares

    A once-in-a-decade opportunity to buy these ASX 200 growth shares before they rocket?

    Is now the time to seize on market weakness to buy these highly rated stocks?

    Read more »

    A smiling man points upwards with both fingers in an exaggerated sideways pose.
    Growth Shares

    Experts say these fantastic ASX growth shares are strong buys

    Analysts have just put buy ratings on these stocks.

    Read more »

    Five guys in suits wearing brightly coloured masks, they are corporate superheroes.
    Best Shares

    Which ASX 200 market sector has been the best performer over 10 years?

    This might surprise you...

    Read more »

    a concerned medical doctor examines an Xray from an imaging machine in a hospital setting.
    Healthcare Shares

    Big ASX news! Pro Medicus shares crash 9% in a week

    What's next for the imaging software company?

    Read more »

    Economic moat
    Blue Chip Shares

    5 top ASX 200 shares with 'no credible competition'

    ASX 200 stocks that can keep the competition at bay enjoy ongoing market advantages.

    Read more »

    A young woman lifts her red glasses with one hand as she takes a closer look at news.
    Broker Notes

    Top brokers name 3 ASX shares to buy today

    Here's what brokers are recommending as buys this week.

    Read more »

    A man looking at his laptop and thinking.
    Technology Shares

    1 ASX 200 tech stock to buy and 1 to hold

    Which one does Goldman Sachs think investors should be buying?

    Read more »

    Contented looking man leans back in his chair at his desk and smiles.
    Share Market News

    5 things to watch on the ASX 200 on Wednesday

    Will the ASX lift again today? Let's find out.

    Read more »

    Frequently Asked Questions

    Yes, the company historically pays two fully franked dividends a year. 

    Pro Medicus generally pays its shareholder dividends in March and October.

    Pro Medicus Ltd listed on the ASX on 10 October 2000.

    PME ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Pro Medicus Ltd

    Pro Medicus Ltd (ASX: PME) is a provider of medical imaging technology globally. The company is recognised as a leading supplier of radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions for medical practices and hospitals.

    Pro Medicus's RIS technology products also include medical accounting, clinical reporting, appointments/scheduling, and marketing/management applications. The company's services to the imaging sector cover workflow mapping and optimisation, network design and implementation, hardware sourcing and configuration, and staff and management training.

    Pro Medicus has offices in Australia, Germany, and the US with its products adopted by many top-tier hospitals and health facilities, particularly in the US market.

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    26 Feb 2026 Anthony Hall Buy 8,146 $993,812
    On-market trade.
    25 Feb 2026 Anthony Hall Buy 9,000 $1,029,690
    On-market trade.
    24 Feb 2026 Sam Hupert Buy 4,500 $489,240
    On-market trade.
    24 Feb 2026 Anthony Hall Buy 8,500 $936,105
    On-market trade.
    23 Feb 2026 Peter Kempen Buy 400 $46,572
    On-market trade.
    13 Feb 2026 Deena Shiff Buy 788 $99,815
    On-market trade.
    13 Feb 2026 Anthony Glenning Buy 2,080 $249,204
    On-market trade.
    29 Dec 2025 Peter Kempen Buy 600 $134,400
    On-market trade. As per announcement - 30/12/2025
    23 Dec 2025 Sam Hupert Buy 2,250 $499,477
    On-market trade.
    23 Dec 2025 Anthony Hall Buy 2,270 $500,103
    On-market trade.
    22 Dec 2025 Sam Hupert Buy 2,250 $498,262
    On-market trade.
    22 Dec 2025 Anthony Hall Buy 2,250 $499,275
    On-market trade.
    03 Sep 2025 Sam Hupert Transfer 50,000 $14,950,000
    Off-market transfer. Estimated value
    12 Mar 2025 Anthony Glenning Buy 50 $10,979
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Sam Aaron Hupert Chief Executive OfficerManaging Director Oct 2007
    Mr Hupert, left general practice in late 1984 to devote himself full time to managing the Group. Sam served as CEO from the time he co-founded the company until October 2007 at which time he stepped down to become an executive director. Sam resumed full time CEO activities in October of 2010.
    Mr Anthony Barry Hall Executive DirectorTechnology Director Jan 1983
    Mr Hall has been principal architect and developer of the core software systems that underpin Visage RIS.
    Mr Peter Terence Kempen Non-Executive ChairmanNon-Executive Director Mar 2008
    Mr Kempen is Chairman of Australasian Leukemia and Lymphoma Group. He is also a Trustee of the Barr Family Foundation and a member of the Boards of St Hilda's College Ltd, University of Melbourne, and the Olivia Newton-John Cancer Research Institute. Peter has previously been Chairman of Patties Food Limited, Chairman of Danks Holdings Limited, Chairman of Ivanhoe Grammar School and Managing Partner of Ernst & Young Corporate Finance Australia. Peter was appointed a Member in the General Division of the Order of Australia (AM) in the 2018 Queen's Birthday Honors. He became Chairman in August 2010 before which he served as a Non-Executive Director of the Company.
    Ms Alice Joan Morrice Williams Non-Executive Director Sep 2021
    Ms Williams is also a non-executive director of Vocus Group, Swimming Australia, Australian Submarine Corporation (ASC Pty Ltd) and Mercer Investments Australia Ltd. She is chair of the Audit & Risk Committee of ASC and Vocus Group and is a member of the Audit & Risk Committee and Due Diligence Committee of Mercer Investments (Australia) Ltd. Alice holds other board positions with Tobacco Free Portfolios and is on the Advisory Council of the Florey Institute of Neuroscience Novell Project. Previous board roles include Director and Chair of the Audit Committee of Cooper Energy, Djerriwarrh Investments, Chair of Nomination, Remuneration and Human Resources Committee and Non-Executive Director of Equity Trustees Ltd, and Nonexecutive member of the Foreign Investment Review Board. Alice is Chair of the Risk committee and serves on the People & Culture committee.
    Ms Deena Robyn Shiff Non-Executive Director Aug 2020
    Ms Shiff is an Independent Board Member of the Global Alliance for Vaccines and Immunization, the multi-lateral global health fund based in Geneva, the Chairman of AROSE (Australian Remote Operations in Space and Earth), and since July 2025, the Chairman of the Australian Telecommunications Alliance. and Chairman of the Care Economy Co Operative Research Centre. She also chairs the International Advisory Board of the Australian Research Centre of Excellence on Automated Decision Making and Society. Deena is Chair of the People & Culture committee and serves on the Risk committee.
    Mr Anthony James Glenning Non-Executive Director May 2016
    Mr Glenning is a fund adviser to Skalata Ventures, investing in early-stage companies to help them scale and grow into sustainable businesses. Anthony has previously been an Investment Director at Starfish Ventures and was the founder and CEO of Tonic Systems and a founding Non-Executive Director of Cameron Systems. He has also held senior software engineering positions at Google and Sun Microsystems Inc. Anthony also serves on the People & Culture committee and Risk committee.
    Dr Leigh Bernard Farrell Non-Executive Director Sep 2017
    Dr Farrell is the Managing Director of AdNED Pty Ltd, non-executive director of both Ena Respiratory Pty Ltd and Axelia Oncology Pty Ltd, a member of the Walter and Eliza Hall Institute of Medical Research Board Commercialization Committee, a member of the Scientific and Industry Advisory Committee of the Australian Research Council Centre for Cryo-electron Microscopy of Membrane Proteins and a member of the Investment Committee for the CUREAtor Plus.Dementia and Cognitive Decline Grants which is funded by the Australian Medical Research Future Fund. Leigh was previously Head of Health Security Systems Australia, a Division of DMTC Ltd, Senior Vice President, Commercial of Certara USA, Inc. where he was responsible for Asia Pacific Commercial. Prior to this, he was Chairman and COO of d3 Medicine LLC, which was acquired by Certara USA, Inc. Leigh also serves on the People & Culture committee and Risk committee.
    Ms Danny English Company Secretary Mar 2023
    -
    Clayton Hatch Chief Financial Officer
    -
    Danny English Company Secretary
    -
    Malte Westerhoff General Manager Europe and Global Chief Technology Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Mr A Hall (multiple shareholdings) 24,144,000 23.11%
    Dr S Hupert (multiple shareholdings) 24,137,660 23.11%
    HSBC Custody Nominees (Australia) Limited 23,739,921 22.73%
    J P Morgan Nominees Australia Limited 7,952,739 7.61%
    Citicorp Nominees Pty Ltd 7,726,022 7.40%
    BNP Paribas Noms Pty Ltd 1,781,046 1.70%
    Mr Peter Terence Kempen & Mrs Elaine Margaret Kempen multiple shareholdings) 629,082 0.60%
    Mr Michael Wu 439,242 0.42%
    Grain Exporters (Australia) Pty Ltd 437,925 0.42%
    National Nominees Limited 402,482 0.39%
    Netwealth Investments Limited 297,897 0.29%
    Mr Stephen Geoffrey Wilson & Ms Denise Adele Prandi 281,417 0.27%
    Mr Colin Gregory Organ 271,000 0.26%
    Mr John Charles Plummer 250,000 0.24%
    Mr Danny Tauber 164,007 0.16%
    Mr Bram Vander Jagt & Mrs Maaike Vander Jagt 140,000 0.13%
    Mr Sean Michael Lambright 127,587 0.12%
    A Haig Retirement Manager Pty Ltd 114,723 0.11%
    Mr Kenneth John Vander Jagt & Mrs Tanya Vander Jagt 103,000 0.10%
    BNP Paribas Noms (Nz) Ltd 90,680 0.09%

    Profile

    since

    Note